Thyroglossal duct cyst (TDC) is a rare condition in adults. This is a report of its presentation and standard treatment with good outcome in adults in a Sub-Saharan tertiary hospital.It is a retrospective review of five adult patients who were managed over a five-year period culled from archived records and casenotes. The three males and two females have a median age of 35 years and a range of 15-74 years. Each of them presented with anterior neck masses while one, in addition, had a painful swelling with a discharging sinus. The median duration of the symptoms was 4.5 years. Four of the cysts were in the infrahyoid location and all the patients had a Sistrunk operation. The median duration of followup was six months, without complications. Surgeons need to have a high level of suspicion for this condition in adults.

BackgroundThe Caprini risk assessment model has been validated in breast cancer surgery patients. However, its utility in our population has not been described. This study evaluated the benefits and risks of the Caprini risk stratification tool and the incidence of venous thromboembolism (VTE) in the 30-day postoperative period among surgical female patients with breast cancer who were hospitalized during their treatment. MethodologyThis is a retrospective review of prospectively collected data of all surgical patients with histologically confirmed breast cancer who were hospitalized between January and December 2018. Caprini score, treatment information, and 30-day outcome of prophylaxis were collated and analyzed using SPSS version 26 (IBM Corp., Armonk, NY, USA). ResultsA total of 167 female patients with breast cancer aged 19 to 75 years were hospitalized during the study period. All patients had invasive ductal carcinoma, and the majority (76.6%) were premenopausal. Two fatal VTE events occurred during hospitalization, giving a 30-day incidence of 1.2%. There was no adverse event from chemoprophylaxis. ConclusionsVTE is rare in hospitalized surgical patients with breast cancer undergoing routine pharmacologic and mechanical prophylaxis. The Caprini tool can identify extremely low-risk patients who require no prophylaxis.

Background: Breast cancer subtypes are often used as therapeutic and prognostic measures; however, it is unclear whether there is an association between molecular subtypes and site-specific metastasis. Our study aimed to evaluate the relationship between molecular subtypes and developing metastasis in specific sites. Methods: We selected 118 breast cancer patients with immunohistochemistry confirmed molecular subtype diagnosed in 2020 and 2021 at the Department of Surgery, University College Hospital, Ibadan. We classified the molecular subtypes into four categories, HR+/HER2-, HR-/HER2+, HR+/HER2+, and triple negative (HR-/HER2-). The different sites of metastasis of interest were lungs, liver, brain, and bone. We used the chi-square test to determine the proportions and significance of the subtypes based on the different sites assessed. Results: According to our study, 45.50%, 18.20%, and 36.40% of patients presented with lungs, liver, and other (multiple organs and contralateral breast) metastasis respectively. Additionally, HR+/HER2- and TNBC patients developed metastasis at a higher rate and account for a combined 90.10% of all metastases (the site-specific distribution was even between both subtypes). Conclusion: Overall, while there are limitations in our study based on sample size, our data shows that some molecular subtypes are associated with a higher risk of metastasis. Additionally, while not significant in our study, breast cancer subtypes are associated with different metastatic sites.